Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non-Small Cell Lung Cancer

Trial Profile

Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non-Small Cell Lung Cancer

Not yet recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Nov 2018

At a glance

  • Drugs Durvalumab (Primary) ; Vactosertib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Sponsors MedPacto
  • Most Recent Events

    • 04 Nov 2018 Status changed from planning to not yet recruiting.
    • 01 Aug 2018 New trial record
    • 24 Jul 2018 According to a MedPacto media release, the company expects to initiate the study in the second half of 2018. The trial will be conducted in Yonsei Severance Hospital and National Cancer Center and is expected to be completed within two years.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top